Benign Prostatic Hyperplasia (BPH) Procedures are expected to grow at a CAGR of 2.3% during 2017 – 2023, according to P&S Market Research
Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time. Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, prostate implants and laser based treatments. Thus, growing aging population acts as a strong driver supporting the increase in the number of BPH procedures performed.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-procedures/report-sample
Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe. France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH. NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-procedures
Some of the other key players operating in the global BPH procedures include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology, Convergent Laser Technologies, Richard Wolf GmbH, Medtronic Plc.
Due to rising prostate issues including growth of major issues like prostate cancer, the market will likely reach US 12 billion in valuation by 2027.
The new cases of prostate ailments and minimally surgical procedures as well as potency and efficacy of the new drugs will drive growth of the benign prostatic hyperplasia treatment market.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=72273 The rise of the disease among middle-aged men is a newly discovered and growing cause of concern in the healthcare sector.
The surrounding campaigns like national prostate health month, and rising awareness of the disease in the region are expected to create new opportunities for players in the benign prostatic hyperplasia treatment market.Request COVID Analysis on Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=72273 Rising Cases Presents a Major Challenge for the Healthcare SectorCurrently, BPH presents the most common form of benign among various tumor cases.
It is estimated that there are over 8 million American men who are suffering from the condition and 22 million patients suffer its mild symptoms.
Moreover, the growth of the tumor can make it difficult to operate on other serious ailments like prostate cancer among people above 90, whose risks is as high as 60%.Request Customization on Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=72273 Rising Elderly Population to Drive Robust Growth GloballyRising geriatric population globally is expected to create significant opportunities for expansion for existing players in the market.
The population is also expected to rise at the fastest rate in the US, Japan, UK, China, Brazil, among others.
The global benign prostatic hyperplasia treatment market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth.
With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each benign prostatic hyperplasia treatment market player in a comprehensive way.
Further, the benign prostatic hyperplasia treatment market report emphasizes the adoption pattern of the benign prostatic hyperplasia treatment market across various industries.The benign prostatic hyperplasia treatment market report highlights the following players:OlympusLISA LaserUrologix, LLCEndo International PlcTeleflex IncorporatedTeva Pharmaceutical Industries Ltd.The benign prostatic hyperplasia treatment market report examines the operating pattern of each player – new product launches, partnerships, and acquisitions – has been examined in detail.Important regions covered in the benign prostatic hyperplasia treatment market report include:North America (U.S., Canada)Europe (U.K., France)Asia Pacific (China, India)Latin America (Brazil, Mexico)The benign prostatic hyperplasia treatment market report takes into consideration the following segments by treatment:Drug ClassMinimally Invasive SurgeriesLaser TherapyRequest for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=4412The benign prostatic hyperplasia treatment market report contain the following end use:HospitalsAmbulatory Surgical CentersSpecialty ClinicsThe benign prostatic hyperplasia treatment market report offers a plethora of insights which include:Changing consumption pattern among individuals globally.Historical and future progress of the global benign prostatic hyperplasia treatment market.Region-wise and country-wise segmentation of the benign prostatic hyperplasia treatment market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global benign prostatic hyperplasia treatment market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global benign prostatic hyperplasia treatment market.The benign prostatic hyperplasia treatment market report answers important questions which include:Which regulatory authorities have granted approval to the application of benign prostatic hyperplasia treatment market in healthcare industry?How will the global benign prostatic hyperplasia treatment market grow over the forecast period?Which end use industry is set to become the leading consumer of benign prostatic hyperplasia treatment market by 2027?What manufacturing techniques are involved in the production of the benign prostatic hyperplasia treatment market?Which regions are the benign prostatic hyperplasia treatment market players targeting to channelize their production portfolio?The benign prostatic hyperplasia treatment market report considers the following years to predict the market growth:Estimated Year: 2027Forecast Year: 2020 – 2027Why Choose Fact.MR?
Fact.MR follows a multi- disciplinary approach to extract information about various industries.
Our analysts perform thorough primary and secondary research to gather data associated with the market.
With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients.
The U.S. benign prostatic hyperplasia (BPH) procedures is expected to grow at a CAGR of 4.2% during 2017-2023.By 2023, the number of BPH procedures performed in the U.S. is expected to reach 215,584.
Growing aging population, rising prevalence of BPH disorders, technological advancements in the BPH procedures and increasing awareness about the BPH disorders and treatments available are the major factors driving the adoption of BPH procedures in the U.S.Download Report Sample at: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sampleMany other therapies are under development phase, robot-guided high energy water ablation (Aquablation) therapy launched by Procept BioRobotics under the name AquaBeam has completed phase III study and has attained CE mark, TGA and MedSafe registration.
The therapy is available in U.S. for investigational purpose.
Aquablation is a waterjet ablation technology that enables heat free and quick removal of prostate tissue for the treatment of BPH.
As per the researchers and study, Aquablation has potential to standardize the BPH surgery and reduce the level of complexities.
Technologically advanced therapies offer benefits over conventional procedures, leading to their high adoption by the urologists for treating BPH.Key player in the U.S. BPH procedures are introducing new advanced products for BPH treatment and gaining public and private insurance coverage.
